Solvonis Therapeutics (LSE:SVNS) EV-to-EBIT : -9.84 (As of May. 29, 2025)

Solvonis Therapeutics EV-to-EBIT Chart

Solvonis Therapeutics Quarterly Data
	May18	May19	May20	May21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial								-5.69	-0.15	-0.38	-1.03	-

Competitive Comparison of Solvonis Therapeutics's EV-to-EBIT

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solvonis Therapeutics's EV-to-EBIT Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's EV-to-EBIT falls into.

Solvonis Therapeutics EV-to-EBIT Calculation

Solvonis Therapeutics's EV-to-EBIT for today is calculated as:

Solvonis Therapeutics's current Enterprise Value is £9.62 Mil.
Solvonis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-0.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics  (LSE:SVNS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Solvonis Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Solvonis Therapeutics's Enterprise Value for the quarter that ended in Sep. 2024 was £2.39 Mil.
Solvonis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-0.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Solvonis Therapeutics Business Description